Gland Pharma block deal: Fosun Pharma divests 99 lakh shares value Rs 2,800 crore
Fosun Pharma held 8,53,93,894 shares, or 51.77% stake, within the pharmaceutical firm as of the quarter ended June 30, 2026, as per BSE knowledge. Following the stake sale, its holding would come right down to round 45.77%.
Kotak Mahindra Mutual Fund, Axis Mutual Fund and ICICI Prudential Mutual Fund have been among the many patrons.
Kotak Mahindra MF purchased 27.93 lakh shares, or 1.69% stake, for Rs 789 crore, whereas Axis MF acquired 13.57 lakh shares, equal to 0.82% stake, for Rs 384 crore. ICICI Prudential Mutual Fund bought 10.39 lakh shares, or 0.63% stake, for Rs 294 crore.
The three mutual funds purchased the shares at a median worth of Rs 2,826.6 per share.
In the meantime, Gland Pharma shares ended Friday’s buying and selling session at Rs 2,932.40 apiece, up 0.84% from the earlier shut of Rs 2,907.90. The inventory had fallen to a low of Rs 2,827 through the session following the block deal.
ALSO READ: Mega NSE IPO coming as Sebi approves Rs 30,000 crore public supplyEarlier on September 1, Gland Pharma knowledgeable the exchanges that america Meals and Drug Administration (USFDA) had carried out a routine Good Manufacturing Follow (GMP) inspection on the firm’s VSEZ Sterile Oncology Formulations Facility and API Facility in Visakhapatnam between August 24 and September 1. The inspection concluded with zero Kind 483 observations.
On August 10, Gland Pharma reported a consolidated web revenue of Rs 317 crore for Q1FY27, up 47% year-on-year from Rs 216 crore within the corresponding quarter final 12 months. Income from operations rose 20% year-on-year to Rs 1,800 crore from Rs 1,506 crore in Q1FY26.
Throughout Q1FY27, the corporate’s quarterly R&D funding stood at Rs 77.2 crore, whereas adjusted EBITDA elevated 37% year-on-year. The adjusted EBITDA margin stood at 28%. The CDMO enterprise contributed 50% of whole income and recorded 20% year-on-year development through the quarter. The B2B enterprise accounted for the remaining 50% of income and grew 19% year-on-year.
Established in Hyderabad in 1978, Gland Pharma has grown from a contract producer of small-volume liquid parenteral merchandise to a generic injectable manufacturing firm with a world footprint throughout 60 nations, together with america, Europe, Canada, Australia, India and different markets.
The corporate primarily operates below a business-to-business (B2B) mannequin and has a observe document in pharmaceutical analysis and growth, manufacturing and advertising and marketing of advanced injectables.
(Disclaimer: Suggestions, recommendations, views and opinions given by the consultants are their very own. These don’t signify the views of Financial Occasions)
